The FDA has granted fast track status to 67Cu-SAR-bisPSMA for metastatic prostate cancer that is resistant to hormone therapy ...

Discover a study that describes a host-intrinsic mechanism responsible for the failure of PD-L1 blockade in ovarian cancer.

Chimerix holds the potential to have the first approval of dordaviprone for treating recurrent H3 K27M mutant high-grade ...

Mayo Clinic researchers have discovered a new immunotherapy target, a cryptic antigen, that may be key in helping the immune ...

Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, provides new insights on the role of TROP2-directed antibody drug conjugates (ADCs) for patients with breast cancer.

To provide updated guidance regarding neoadjuvant chemotherapy (NACT) and primary cytoreductive surgery (PCS) among patients with stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal ...

scrutinized the efficacy and safety of poly (ADP-ribose) polymerase inhibitors (PARPi) as a maintenance treatment in 75 Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC). The ...

The single-cell landscape of small cell neuroendocrine cervical carcinoma revealed the tumor heterogeneity and the molecular subtypes, laying the foundation for exploring tumor etiology, precision ...

This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. This work is licensed under a Creative Commons Attribution 4.0 International ...

TORL-1-23 was well tolerated and showed efficacy in heavily pretreated, CLDN6-positive advanced solid tumors, including platinum-resistant ovarian cancer.

George Coukos, MD, PhD, Department of Oncology, University Hospital of Lausanne, Rue du Bugnon 46, Lausanne 1011, Switzerland; e-mail: [email protected]. If you have the appropriate software installed ...

Results Adding additional points for high-grade serous ovarian cancer <60 (HGSOC=+2) and adding grade score to those with triple-negative breast cancer, while reducing the score for those with HER2+ ...